IRWD
Ironwood Pharmaceuticals Inc
NASDAQ · Biotechnology
$4.56
+0.11 (+2.47%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 357.11M | 377.10M | 79.96M | 73.58M | 81.79M |
| Net Income | 894.7K | 850.3K | 13.20M | 12.49M | 15.09M |
| EPS | — | — | — | — | — |
| Profit Margin | 0.3% | 0.2% | 16.5% | 17.0% | 18.5% |
| Rev Growth | -5.3% | -5.3% | +4.0% | +11.9% | +19.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 140.16M | 140.16M | 217.49M | 202.65M | 191.91M |
| Total Equity | 230.75M | 230.75M | 435.61M | 432.39M | 478.38M |
| D/E Ratio | 0.61 | 0.61 | 0.50 | 0.47 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 97.33M | 97.64M | 23.20M | 23.02M | 27.07M |
| Free Cash Flow | — | — | 16.46M | 13.98M | 17.94M |